Skip to content

Study · Non-randomized trial · n = 50 · 2020

5 results

Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series.

Armstrong D, Forbes A, Jeppesen PB, Lee HM, Nagy P, Seidner DL

Clinical nutrition (Edinburgh, Scotland)23 Aug 2019Cited by 28 (Europe PMC)

PMID31522784 (opens in a new tab)DOI10.1016/j.clnu.2019.08.020 (opens in a new tab)PepBankPUB-31522784
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In teduglutide-treated adults with SBS-IF, post-exposure colon polyps occurred in 18% (9/50), versus baseline 12% (9/73).

    In plain wordsIn adults receiving teduglutide, colon polyps occurred in 18% after exposure and 12% at baseline, with different denominators.

    Peptide
    Teduglutide
    Outcome
    Not applicablePost-exposure colon polyps
    Study

    n = 50

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.05 mg/kg/day · 24 and 36 monthsAs given in this study (human).

    Measurements

    Patients with colon polyps at baseline
    12%
    Baseline colonoscopy, 9/73 patients
    Patients with colon polyps at baseline
    9 patients
    Baseline colonoscopy, of 73
    Patients with colon polyps post-exposure
    18%
    Post-exposure colonoscopy, 9/50 patients
    Patients with colon polyps post-exposure
    9 patients
    Post-exposure colonoscopy, of 50

    Source sentences

    Summary
    Colon polyps were reported at baseline in 12% (9/73) of patients and post-exposure in 18% (9/50) of patients.
    1 context sentence
    Summary · context
    evaluated electronic case report form data for baseline colonoscopies (performed before treatment) and for surveillance or end-of-study (performed after treatment with teduglutide 0.05 mg/kg/day for 24 and 36 months) post-exposure procedures.
  2. 02HumanNon-randomized trialSafety outcome

    Among teduglutide-treated adults with available polyp histology, 5 had adenomas, including 1 serrated and 4 tubular.

    In plain wordsIn adults receiving teduglutide with available polyp histology, 5 had adenomas, including 1 serrated and 4 tubular.

    Peptide
    Teduglutide
    Outcome
    Not applicableAdenomas
    Study

    n = 7

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.05 mg/kg/day · 24 and 36 monthsAs given in this study (human).

    Measurements

    Patients with adenomas
    5 patients
    Of 7 with histology
    Serrated adenomas
    1 patients
    Of 7 with histology
    Tubular adenomas
    4 patients
    Of 7 with histology

    Source sentences

    Summary
    On histology, available for 7 patients, 5 had adenomas (1 serrated, 4 tubular) and none had malignancy or high-grade dysplasia.
    1 context sentence
    Summary · context
    evaluated electronic case report form data for baseline colonoscopies (performed before treatment) and for surveillance or end-of-study (performed after treatment with teduglutide 0.05 mg/kg/day for 24 and 36 months) post-exposure procedures.
  3. 03HumanNon-randomized trialSafety outcome

    Among teduglutide-treated adults with available polyp histology, none had malignancy.

    In plain wordsIn adults receiving teduglutide with available polyp histology, none had cancer.

    Peptide
    Teduglutide
    Outcome
    Not applicableMalignancy
    Study

    n = 7

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.05 mg/kg/day · 24 and 36 monthsAs given in this study (human).

    Source sentences

    Summary
    On histology, available for 7 patients, 5 had adenomas (1 serrated, 4 tubular) and none had malignancy or high-grade dysplasia.
    1 context sentence
    Summary · context
    evaluated electronic case report form data for baseline colonoscopies (performed before treatment) and for surveillance or end-of-study (performed after treatment with teduglutide 0.05 mg/kg/day for 24 and 36 months) post-exposure procedures.
  4. 04HumanNon-randomized trialSafety outcome

    Among teduglutide-treated adults with available polyp histology, none had high-grade dysplasia.

    In plain wordsIn adults receiving teduglutide with available polyp histology, none had high-grade dysplasia.

    Peptide
    Teduglutide
    Outcome
    Not applicableHigh-grade dysplasia
    Study

    n = 7

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.05 mg/kg/day · 24 and 36 monthsAs given in this study (human).

    Source sentences

    Summary
    On histology, available for 7 patients, 5 had adenomas (1 serrated, 4 tubular) and none had malignancy or high-grade dysplasia.
    1 context sentence
    Summary · context
    evaluated electronic case report form data for baseline colonoscopies (performed before treatment) and for surveillance or end-of-study (performed after treatment with teduglutide 0.05 mg/kg/day for 24 and 36 months) post-exposure procedures.
  5. 05HumanNon-randomized trialSafety outcome

    In teduglutide-treated adults with SBS-IF, two patients had polyps both at baseline and after exposure.

    In plain wordsIn adults receiving teduglutide, two patients had polyps before and after treatment.

    Peptide
    Teduglutide
    Outcome
    Not applicablePolyps at baseline and post-exposure
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.05 mg/kg/day · 24 and 36 monthsAs given in this study (human).

    Measurements

    Patients with polyps at both baseline and post-exposure
    2 patients
    Teduglutide-treated adults

    Source sentences

    Summary
    Two had polyps both at baseline and post-exposure.
    1 context sentence
    Summary · context
    evaluated electronic case report form data for baseline colonoscopies (performed before treatment) and for surveillance or end-of-study (performed after treatment with teduglutide 0.05 mg/kg/day for 24 and 36 months) post-exposure procedures.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.